Slieker, Roderick C. http://orcid.org/0000-0003-0961-9152
Münch, Magnus http://orcid.org/0000-0001-9659-2044
Donnelly, Louise A. http://orcid.org/0000-0003-4902-1040
Bouland, Gerard A. http://orcid.org/0000-0002-4311-8725
Dragan, Iulian
Kuznetsov, Dmitry
Elders, Petra J. M. http://orcid.org/0000-0002-5907-7219
Rutter, Guy A. http://orcid.org/0000-0001-6360-0343
Ibberson, Mark http://orcid.org/0000-0003-3152-5670
Pearson, Ewan R. http://orcid.org/0000-0001-9237-8585
’t Hart, Leen M. http://orcid.org/0000-0003-4401-2938
van de Wiel, Mark A. http://orcid.org/0000-0003-4780-8472
Beulens, Joline W. J. http://orcid.org/0000-0002-4181-0937
Funding for this research was provided by:
IMI-RHAPSODY (115881)
Article History
Received: 3 July 2023
Accepted: 5 January 2024
First Online: 19 February 2024
Acknowledgements
: We acknowledge the support of the Health Informatics Centre, University of Dundee for managing and supplying the anonymised data. The authors wish to thank the Core-IT group of SIB Swiss Institute of Bioinformatics and in particular J. Molina for expert technical help in setting up and maintaining the federated database. The authors thank participants of the included cohorts.
: Summary statistics of lipidomic, proteomic and metabolomic data are available from a Shiny dashboard at ExternalRef removed. The generated metabolomic, lipidomic and proteomic data in the DCS, GoDARTS and All New Diabetics In Scania (ANDIS) are considered sensitive patient data and are therefore not publicly available, in compliance with the European privacy regulations governed by the General Data Protection Regulation (GDPR) and according to limitations included in the informed consents signed by the study participants. For the DCS and GoDARTS proteomics data, restricted access for the proteomics data can be obtained via the European Genome/Phenome archive under accession number EGAD00010002447. Metabolomics and lipidomics (DCS, GoDARTS, ANDIS) data are available upon request by contacting the senior authors (LMtH, lmthart@lumc.nl), ERP (E.Z.Pearson@dundee.ac.uk), JWJB (j.beulens@amsterdamumc.nl) and GAR (g.rutter@imperial.ac.uk). Requests should include name and contact details of the person requesting the data, which molecular data and clinical variables are requested, and the purpose of the request.
: This project received funding from the Innovative Medicines Initiative 2 Joint Undertaking, under grant agreement no. 115881 (RHAPSODY). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI), under contract no. 16.0097. The DCS cohort was supported by grants from the Netherlands Organisation for Health Research and Development (113102006, 459001015). GAR was funded by a Wellcome Trust Investigator Award (212625/Z/18/Z), UK MRC Programme grant (MR/R022259/1), CRCHUM start-up funds, an Innovation Canada John R. Evans Leader Award (CFI 42649), JDRF (JDRF 4-SRA-2023-1182-S-N) and CIHR (CIHR-IRSC:0682002550) project grants.
: GAR has received grant funding from and is a consultant for Sun Pharmaceutical Industries. JWJB is a former member of the editorial board of <i>Diabetologia</i>. The other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work
: RCS, MM, LMtH, MAvdW and JWJB conceived the study. RCS and MM performed the analyses. GAB, ID, DK and MI developed the federated nodes that were used in the current study. GAR oversaw biomarker shipments and quality control analyses leading to the selection of cohorts. LAD, PJME, ERP, LMtH and JWJB acquired the cohort data. RCS and JWJB drafted the manuscript. All authors critically revised the manuscript and approved the final version. RCS is the guarantor of the work.